|
Actavis extends portfolio with five new products in the US |
|
|
|
06 Jul 2006 |
REYKJAVIK, Iceland | Jul 05, 2006 | Actavis Group (ICEX: ACT) today announces the launch of five new products in the United States, all of which will be marketed under the Group's own label.
The five products include:
Dantrolene: the generic equivalent of Dantrium, a product already manufactured by Procter & Gamble to treat chronic spasticity and malignant hyperthermia. It is produced in three different strengths - 25, 50 and 100mg capsules.
Isradipine: the generic equivalent of DynaCirc, a product of Reliant Pharmaceutical. It is used for the treatment of hypertension and produced in two different strengths - 2.5 and 5mg capsules.
Amantadine: is the generic equivalent of Symmetrel, a product of Endo Pharmaceutical. It is used to treat symptoms of influenza A virus. It is also prescribed for the treatment of Parkinson's and drug-induced extra-pyramidal reactions. It is only produced in 100mg capsules.
Dipyridamole: is the generic equivalent of Persantine, a product of Boehringer Ingelheim. Dipyridamole is an anti-platelet, used to reduce the risk of blood clots after heart valve replacement. It is produced in three different strengths - tablets containing 25, 50 and 75mg.
Spironolactone: is the generic equivalent of Aldactone, a product of Pfizer. Spironolactone is used for the management of primary hyperaldosteronism, edema, hypertension, and hypokalemia. It is now produced in three different strengths 25, 50 and 100mg tablets.
Commenting on the new product launches, President of North America sales Sigurdur Oli Olafsson, said:
"These product launches lend additional support to our growing portfolio in the US market and are a further demonstration of the strength of our broad pipeline. We have had a strong first half of the year and expect to launch a total of 15 generic products during 2006, which will drive our growth in this important market. We also remain on course to file at least 30 new ANDAs this year."
Enquiries:
Halldor Kristmannsson, VP, Corporate Communications, tel. +354 535 2325/ +354 840 3425, email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Sean Leous, Financial Dynamics in New York, + 1 212 850 5755
SOURCE: Actavis Group |
